HOOKIPA PHARMA INC (HOOK)
US43906K1007 - Common Stock
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns.
HOOK Stock Earnings: HOOKIPA Pharma Beats EPS, Beats Revenue for Q1 2024
HOOK stock results show that HOOKIPA Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
HOOK Stock Earnings: HOOKIPA Pharma Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HOOKIPA Pharma (NASDAQ:HOOK) just reported results for the first quarter of 202...
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or...
Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or...
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
NEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority...
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023
HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HOOKIPA Pharma (NASDAQ:HOOK) just reported results for the fourth quarter of 20...
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in...
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...
Hookipa to cut 30% of workforce in wake of Roche deal termination (NASDAQ:HOOK)
Hookipa (HOOK) stock fell 15% after the company said it was cutting 30% of its workforce amid news Roche had terminated a collaboration deal for the drug HB-700. Read more here.
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious...
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...
HOOKIPA Pharma files to sell 15M shares for holders (NASDAQ:HOOK)
HOOKIPA Pharma files a prospectus for the proposed resale of 15M shares of common stock by a selling stockholder. This is not an offer to sell securities.